草分枝杆菌F.U.36注射液预防过敏性紫癜复发效果及其对免疫功能的影响

摘要

Objective To explore the effect of Mycobacterium phlei F. U. 36 injection on relapse prevention of Henoch-Schonlein purpura(HSP) and immunological function. Methods 76 children with HSP were randomly divided into Mycobacterium phlei therapy group ( n = 38 ) and general control group ( n = 38 ). Two groups were all treated by routine medicine. In addition, Mycobacterium phlei injection was given to Mycobacterium phlei therapy group. The relapse rate was recorded within 6 months and 1 year after course of treatment. The antigen markers of T-lymphocyte, including CD3, CD4 and CD8 expression on the surface of peripheral blood lymphocytes were analyzed by flow cytometry, the serum levels of IgA, IgG and IgM were detected before and after treatment. And 15 cases of healthy children were selected as normal control group. Results The relapse rate in Mycobacterium phlei therapy group was significantly lower than that of control group ( P ＜ 0. 05 ) . The level of CD3, CD4 , CD8, CD4/CD8, IgG, IgA and IgM between two HSP groups before trentment had no significant difference(P ＞0. 05). But the level of CD3,CD4 cell, ratio of CD4/CD8 cell in HSP groups were significantly lower than those in normal control group ( P ＜ 0. 05) , and the serum concentration of IgA in HSP group was significantly higher than that in normal control group(P ＜0. 05). After treatment by Mycobacterium phlei injection, the level of CD3 ,CD4 and ratio of CD4/CDg in Mycobacterium phlei therapy group were significantly higher than those in general control group(P ＜0. 05) , meanwhile IgA in Mycobacterium phlei therapy group was significantly lower than that in general control group ( P ＜ 0. 05). Conclusion Mycobacterium phlei F. U. 36 injection is effective for prevention of relapse of HSP. Its mechanism is related to accelerating the recovery of HSP immune abnormality.%目的 探讨草分枝杆菌F.U.36注射液(乌体林斯)预防过敏性紫癜(HSP)复发的疗效及其对免疫功能的影响.方法 将76例HSP患儿随机分为草分枝杆菌组(n=38)和一般治疗组(n=38),在常规治疗基础上,草分枝杆菌组加用草分枝杆菌F.U.36注射液肌内注射,观察两种治疗方法对预防HSP复发的疗效及6个月和1年内的复发情况,同时检测治疗前后的外周血T淋巴细胞亚群CD3、CD4、CD8、CD4/CD8及免疫球蛋白IgG、IgA、IgM水平.另取15例正常儿童作为治疗前健康对照.结果 草分枝杆菌组在治疗后6个月及1年内复发率均低于一般治疗组(P＜0.05).治疗前两组HSP患儿外周血CD3、CD4、CD8、CD4/CD8、IgG、IgA、IgM比较,差异均无统计学意义(P＞0.05),但CD3、CD4及CD4/CD8低于健康组(P＜0.05),IgA高于健康组(P＜0.05).草分枝杆菌组经草分枝杆菌F.U.36注射液治疗后,CD3、CD4、CD4/CD8明显高于一般治疗组,而IgA低于一般治疗组,差异均有统计学意义(P＜0.05).结论 草分枝杆菌F.U.36注射液肌内注射对预防HSP复发有一定的疗效,其机制可能与促进HSP免疫异常恢复有关.